Authors: Mazzali, M Hughes, J Kim, YG Jefferson, JA Kang, DH Gordon, KL Lan, HY Kivlighn, S Johnson, RJ

Citation: M. Mazzali et al., Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism, HYPERTENSIO, 38(5), 2001, pp. 1101-1106

Authors: Kim, YG Huang, XR Suga, S Mazzali, M Tang, DJ Metz, C Bucala, R Kivlighn, S Johnson, RJ Lan, HY

Citation: Yg. Kim et al., Involvement of macrophage migration inhibitory factor (MIF) in experimental uric acid nephropathy, MOL MED, 6(10), 2000, pp. 837-848

Authors: Strawn, WB Chappell, MC Dean, RH Kivlighn, S Ferrario, CM

Citation: Wb. Strawn et al., Inhibition of early atherogenesis by losartan in monkeys with diet-inducedhypercholesterolemia, CIRCULATION, 101(13), 2000, pp. 1586-1593

Authors: Alderman, MH Cohen, H Madhavan, S Kivlighn, S

Citation: Mh. Alderman et al., Serum uric acid and cardiovascular events in successfully treated hypertensive patients, HYPERTENSIO, 34(1), 1999, pp. 144-150

Authors: Nishikibe, M Ohta, H Okada, M Ishikawa, K Hayama, T Fukuroda, T Noguchi, K Saito, M Kanoh, T Ozaki, S Kamei, T Hara, K William, D Kivlighn, S Krause, S Gabel, R Zingaro, G Nolan, N O'Brien, J Clayton, F Lynch, J Pettibone, D Siegl, P

Citation: M. Nishikibe et al., Pharmacological properties of J-104132 (L-753,037), a potent, orally active, mixed ETA/ETB endothelin receptor antagonist, J PHARM EXP, 289(3), 1999, pp. 1262-1270